Gilead Sciences Inc. (GILD)
106.83
-0.25 (-0.23%)
At close: Mar 24, 2025, 3:59 PM
107.20
0.35%
After-hours: Mar 24, 2025, 07:55 PM EDT
-0.23% (1D)
| Bid | 106.3 |
| Market Cap | 133.04B |
| Revenue (ttm) | 28.69B |
| Net Income (ttm) | 478.98M |
| EPS (ttm) | 4.61 |
| PE Ratio (ttm) | 23.17 |
| Forward PE | 12.41 |
| Analyst | Buy |
| Ask | 107.17 |
| Volume | 4,697,751 |
| Avg. Volume (20D) | 8,377,437 |
| Open | 107.01 |
| Previous Close | 107.08 |
| Day's Range | 106.10 - 107.38 |
| 52-Week Range | 62.07 - 119.96 |
| Beta | 0.24 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, V...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jan 22, 1992
Employees 17,600
Stock Exchange NASDAQ
Ticker Symbol GILD
Website https://www.gilead.com
Analyst Forecast
According to 25 analyst ratings, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $100, which is a decrease of -6.39% from the latest price.
Stock ForecastsNext Earnings Release
Gilead Sciences Inc. is scheduled to release its earnings on Apr 24, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
-2.47%
Gilead Sciences shares are trading lower after rep...
Unlock content with
Pro Subscription
1 month ago
+7.46%
Gilead Sciences shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 adjusted EPS guidance above estimates.
